相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring
Assaf A. Barg et al.
HAEMOPHILIA (2021)
WFH Guidelines for the Management of Hemophilia, 3rd edition
Alok Srivastava et al.
HAEMOPHILIA (2020)
A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X
Kenichi Ogiwara et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2020)
Factor XIa-triggered thrombin generation in severe haemophilia A
Michael J. R. Desborough et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Novel Thermostable Inhibitor of Contact Activation Tica Effectively Blocks Contact Activation in Low Tissue Factor Thrombin Generation
Tom Van de Berg et al.
BLOOD (2019)
Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FXIa and FXIa activation
Donald F. Brophy et al.
HAEMOPHILIA (2018)
Elevated coagulation factor levels affect the tissue factor-threshold in thrombin generation
Inge M. Rietveld et al.
THROMBOSIS RESEARCH (2018)
Thrombin generation in low plasma volumes
Saartje Bloemen et al.
THROMBOSIS JOURNAL (2018)
Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH
Y. Dargaud et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
Daniel Verhoef et al.
NATURE COMMUNICATIONS (2017)
Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
Peter J. Lenting et al.
BLOOD (2017)
Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive
E. K. Waters et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors
S. V. Antunes et al.
HAEMOPHILIA (2014)
Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A
P. Quade-Lyssy et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation
A. Muto et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A
Corien L. Eckhardt et al.
BLOOD (2013)
Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice
Peter Milanov et al.
BLOOD (2012)
Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A
M. Ninivaggi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors
Cindy Leissinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors
B. A. Konkle et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Formation of factors IXa and Xa by the extrinsic pathway - Differential regulation by tissue factor pathway inhibitor and antithrombin III
G Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The epidemiology of inhibitors in haemophilia A: a systematic review
J Wight et al.
HAEMOPHILIA (2003)
Calibrated automated thrombin generation measurement in clotting plasma
HC Hemker et al.
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2003)
分享论文
